特発性肺線維症市場：薬剤別、投与経路別、流通チャネル別、地域別

特発性肺線維症市場は、2025年には49億5,000万米ドルと推定され、2032年には88億7,590万米ドルに達すると予測され、2025年から2032年までの年間平均成長率（CAGR）は8.7%で成長すると予測されています。

特発性肺線維症（IPF）は、主に高齢者の肺に発症し、通常の間質性肺炎（UIP）の病理組織学的パターンおよび/または放射線学的パターンを伴う、原因不明の慢性で進行性の線維化間質性肺炎の特殊な形態です。IPFの診断には、他の特発性間質性肺炎（IIP）や、環境暴露、薬物、結合組織疾患に関連した間質性肺疾患（ILD）を含む、他の形態の間質性肺炎の除外が必要です。

市場力学

特発性肺線維症の有病率の増加が市場成長の原動力になると予想されます。例えば、2021年7月、国立医学図書館が発表した報告書によると、特発性肺線維症の有病率は、2020年には世界で10万人当たり13～20人でした。米国では2020年に約10万人が罹患し、毎年3万人から4万人が新たに診断されています。

National Center for Biotechnology Informationが発表したレポートによると、インドにおける特発性肺線維症の有病率は、2021年には約13.7％になることが判明しています。

さらに、特発性肺線維症の有病率の増加により、主要市場プレーヤーは新製品の上市に注力しており、これが予測期間中の市場成長を促進すると予想されます。例えば、2022年5月、ジェネリック医薬品とバイオシミラー医薬品の世界的リーダーであるサンドは、特発性肺線維症（IPF）患者を治療するために、バイオテクノロジー企業であるジェネンテックのエスブリエットと同等の初のAB格（抗体）（完全代替可能）であるピルフェニドンのジェネリック医薬品を米国で発売すると発表しました。この内服薬は、専門薬局を通じて患者に処方されます。

本調査の主な特徴

• 本レポートでは、世界の特発性肺線維症市場を詳細に分析し、2024年を基準年として、2025年から2032年の予測期間における市場規模（USD Mn）および複合年間成長率（CAGR%）を提供しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を解明し、この市場の魅力的な投資提案マトリクスについて説明しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 世界の特発性肺線維症市場における主要企業を、企業ハイライト、製品ポートフォリオ、主要ハイライト、財務実績、戦略などのパラメータに基づいてプロファイルしています。本調査の対象となる主要企業には、Genentech, Inc、AstraZeneca、Blade Therapeutics、Bristol-Myers Squibb Company、Cipla Inc.、F. Hoffmann-La Roche、FibroGen, Inc.、Galapagos NV、MediciNova, Inc.、Merck &Co, Inc.、Promedior, Inc.、Prometic Life Sciences Inc.、Daewoong Pharmaceutical（India）Pvt Ltd、Sandoz International GmbH（Novartis）、Algernon Pharmaceuticals Inc.
• 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界の特発性肺線維症市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
• 利害関係者は、世界の特発性肺線維症市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 市場の魅力分析
  • 市場機会
  • 製品の発売
  • 合併、買収、コラボレーション
  • 規制ガイドラインとコンプライアンス
  • 主な発展
  • 市場動向
  • PEST分析
  • 疫学
  • PORTERの分析
  • 規制シナリオ
  • ブランド分析
  • 価格分析
  • パイプライン分析

第4章 世界の特発性肺線維症市場、薬剤別、2020年～2032年

• ピルフェニドン
• ニンテダニブ
• その他（インターフェロンγ-1bなど）

第5章 世界の特発性肺線維症市場、投与経路別、2020年～2032年

• 経口
• 非経口

第6章 世界の特発性肺線維症市場、流通チャネル別、2020年～2032年

• 病院薬局
• 小売薬局
• オンライン薬局

第7章 世界の特発性肺線維症市場、地域別、2020年～2032年

• 北米
  • 米国
  • カナダ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
  • その他ラテンアメリカ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • フランス
  • スペイン
  • ロシア
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • ASEAN
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• 中東
  • GCC
  • イスラエル
  • その他中東
• アフリカ
  • 北アフリカ
  • 中央アフリカ
  • 南アフリカ

第8章 競合情勢

• Genentech, Inc.
• Boehringer Ingelheim International GmbH.
• Avalyn Pharma, Inc.
• AstraZeneca
• Blade Therapeutics
• Bristol-Myers Squibb Company
• Cipla Inc.
• F. Hoffmann-La Roche
• FibroGen, Inc.
• Galapagos NV
• MediciNova, Inc.
• Merck & Co., Inc.
• Promedior, Inc.
• Prometic Life Sciences Inc.
• Daewoong Pharmaceutical（India）Pvt Ltd.
• Sandoz International GmbH（Novartis）
• Algernon Pharmaceuticals Inc.

第9章 セクション

• 調査手法
• 出版社について

Idiopathic Pulmonary Fibrosis Market is estimated to be valued at USD 4,950 Mn in 2025 and is expected to reach USD 8,875.9 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032.

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults, in the lungs, and is associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP). The diagnosis of IPF requires exclusion of other forms of interstitial pneumonia including other idiopathic interstitial pneumonias (IIP) and interstitial lung disease (ILD) associated with environmental exposure, medication, or connective tissue disease.

Market Dynamics

Increasing prevalence of Idiopathic pulmonary fibrosis is expected to drive the market growth. For instance, in July 2021, according to the report published by National Library of Medicine, the prevelance of idiopathic pulmonary fibrosis was 13 to 20 per 100,000 people worldwide in 2020. About 100,000 people were affected in the U.S., in 2020, whereas 30,000 to 40,000 new cases are diagnosed every year.

According to the report published by National Center for Biotechnology Information, the prevalence of Idiopathic pulmonary fibrosis in India was found to be approximately 13.7% in 2021.

Furthermore, due to increasing prevalence of Idiopathic pulmonary fibrosis, the key market players are focusing on new product launches, and this is expected to drive the market growth over the forecast period. For instance, in May 2022, Sandoz, a global leader in generic and biosimilar medicines, announced the launch of its generic Pirfenidone in the U.S., the first AB-rated (Antibody)(fully substitutable) equivalent to Genentech's, a biotechnology company, Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF). This oral medicine is prescribed to patients via specialty pharmacies.

Key features of the study

• This report provides in-depth analysis of the global Idiopathic pulmonary fibrosis market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global Idiopathic pulmonary fibrosis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Genentech, Inc., Boehringer Ingelheim International GmbH, Avalyn Pharma, Inc., AstraZeneca, Blade Therapeutics, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV, MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., Prometic Life Sciences Inc., Daewoong Pharmaceutical (India) Pvt Ltd, Sandoz International GmbH (Novartis), and Algernon Pharmaceuticals Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global Idiopathic pulmonary fibrosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Idiopathic pulmonary fibrosis market.

Market Segmentation

• Global Idiopathic pulmonary fibrosis market, By Drug
  • Pirfenidone
  • Nintedanib
  • Others (Interferon gamma-1b and Others)
• Global Idiopathic pulmonary fibrosis market, By Route of Administration
  • Oral
  • Parenteral
• Global Idiopathic pulmonary fibrosis market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Idiopathic pulmonary fibrosis market, By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Genentech, Inc.
  • Boehringer Ingelheim International GmbH
  • Avalyn Pharma, Inc.
  • AstraZeneca
  • Blade Therapeutics
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Hoffmann-La Roche
  • FibroGen, Inc.
  • Galapagos NV
  • MediciNova, Inc.
  • Merck & Co., Inc.
  • Promedior, Inc.
  • Prometic Life Sciences Inc.
  • Daewoong Pharmaceutical (India) Pvt Ltd.
  • Sandoz International GmbH (Novartis)
  • Algernon Pharmaceuticals Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Attractiveness Analysis
  • Market Opportunities
  • Product Launches
  • Merger, Acquisition, Collaboration
  • Regulatory Guideline and Compliances
  • Key Developments
  • Market Trends
  • PEST Analysis
  • Epidemiology
  • PORTER's Analysis
  • Regulatory Scenario
  • Brand Analysis
  • Pricing Analysis
  • Pipeline Analysis

4. Global Idiopathic Pulmonary Fibrosis Market, By Drug, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pirfenidone
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Nintedanib
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others (Interferon gamma-1b and Others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segments Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Idiopathic Pulmonary Fibrosis Market, By Region, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-Region, 2020 - 2032, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Genentech, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Boehringer Ingelheim International GmbH.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Avalyn Pharma, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Blade Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cipla Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• F. Hoffmann-La Roche
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• FibroGen, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Galapagos NV
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
• MediciNova, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Promedior, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Prometic Life Sciences Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Daewoong Pharmaceutical (India) Pvt Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sandoz International GmbH (Novartis)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Algernon Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

9. Section

• Research Methodology
• About Us